Latest News in Cancer
Stay updated with the most recent articles and resources.
Main Topics
Asciminib is approved by the USFDA for newly diagnosed chronic myeloid leukemia
On October 29, 2024, the FDA granted accelerated approval to asciminib (Scemblix) for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase....
Zolbetuximab-clzb with chemotherapy is approved by the USFDA for gastric or gastroesophageal junction adenocarcinoma
On October 18, 2024, the FDA approved zolbetuximab-clzb (Vyloy) combined with fluoropyrimidine- and platinum-based chemotherapy for first-line treatment of adults with locally advanced unresectable or...
Inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer
On October 10, 2024, the FDA approved inavolisib (Itovebi) combined with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer. The...
Neoadjuvant/adjuvant nivolumab is approved by the USFDA for resectable non-small cell lung cancer
On October 3, 2024, the Food and Drug Administration sanctioned nivolumab (Opdivo, Bristol Myers Squibb Company) in conjunction with platinum-doublet chemotherapy as neoadjuvant therapy,...
Selpercatinib is approved by the USFDA for medullary thyroid cancer with a RET mutation
On September 27, 2024, the FDA granted traditional approval to selpercatinib (Retevmo) for treating advanced or metastatic medullary thyroid cancer (MTC) with RET mutations in...
Latest therapies in the treatment of hematological malignancies
Introduction Hematological malignancies, such as leukemias, lymphomas, and multiple myeloma, are a heterogeneous group of cancers that arise in the bone marrow and lymphatic...
Osimertinib is approved by the USFDA for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy
On September 25, 2024, the FDA approved osimertinib (Tagrisso) for adults with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) with specific EGFR...
Isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone is approved by the USFDA for newly diagnosed multiple myeloma
The FDA has licensed isatuximab-irfc in combination with bortezomib, lenalidomide, and dexamethasone (Isa-VRd) for patients with newly diagnosed multiple myeloma who are not candidates for...
Amivantamab-vmjw with carboplatin and pemetrexed is approved by the USFDA for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations
The FDA has approved Amivantamab-vmjw in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with...
Pembrolizumab with chemotherapy is approved by the USFDA for unresectable advanced or metastatic malignant pleural mesothelioma
The FDA approved pembrolizumab (Keytruda) in combination with chemotherapy for the treatment of unresectable, advanced, or metastatic malignant pleural mesothelioma. This is a great leap...
Kisqali with an aromatase inhibitor and Kisqali Femara Co-Pack is approved by the USFDA for early high-risk breast cancer
The FDA has approved Kisqali (ribociclib) plus an aromatase inhibitor and the Kisqali-Femara Co-Pack for early, high-risk breast cancer. The approval extends the use of...
Bridging The Gaps In CAR T Cell therapy
Chimeric Antigen Receptor (CAR) T-cell therapy has transformed the treatment of hematologic malignancies but is confronting hurdles in the context of solid tumors because of...
Need help? Our team is ready to assist you.
We wish a speedy recovery for your loved ones.